TradingView
TradeWithTyler
May 16, 2019 1:12 AM

CLRB Phase 1 Success 

Cellectar Biosciences, Inc.NASDAQ

Description

Positive news today "CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma". This stock Shs Float is 5.15M, and Market Cap 14.76M.
More